<DOC>
	<DOCNO>NCT01242826</DOCNO>
	<brief_summary>This trial conduct Asia . The aim clinical trial investigate pharmacokinetic property ( rate trial drug eliminate body ) single subcutaneous ( skin ) injection biphasic insulin aspart 50 ( BIAsp 50 ) . In addition , safety tolerability BIAsp 50 observe</brief_summary>
	<brief_title>Investigation Pharmacokinetic Properties Biphasic Insulin Aspart 50 Healthy Chinese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Considered generally healthy upon completion medical history , physical examination , vital sign electrocardiogram ( ECG ) , judge Investigator ( Physician ) Body Mass Index ( BMI ) : 19.024.0 kg/m2 ( inclusive ) Clinically significant abnormal haematology , biochemistry , lipids urinalysis screening test , judge Investigator ( Physician ) A history illness , opinion Investigator ( Physician ) , might confound result trial pose risk administer trial product subject Subject donate blood plasma past month 400 mL within 3 month prior screen ( trial entry ) Not able willing refrain smoking inpatient period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>